Towards biobanking technologies for natural and bioengineered multicellular placental constructs

Biomaterials
Olena PogozhykhDenys Pogozhykh

Abstract

Clinical application of a large variety of biomaterials is limited by the imperfections in storage technology. Perspective approaches utilizing low-temperature storage are especially challenging for multicellular structures, such as tissues, organs, and bioengineered constructs. Placenta, as a temporary organ, is a widely available unique biological material, being among the most promising sources of various cells and tissues for clinical and experimental use in regenerative medicine and tissue engineering. The aim of this study was to analyse the mechanisms of cryoinjuries in different placental tissues and bioengineered constructs as well as to support the viability after low temperature storage, which would contribute to development of efficient biobanking technologies. This study shows that specificity of cryodamage depends on the structure of the studied object, intercellular bonds, as well as interaction of its components with cryoprotective agents. Remarkably, it was possible to efficiently isolate cells after thawing from all of the studied tissues. While the outcome was lower in comparison to the native non-frozen samples, the phenotype and expression levels of pluripotency genes remained unaffected. Further progress i...Continue Reading

Citations

Jun 10, 2020·International Journal of Molecular Sciences·Olena PogozhykhConstança Figueiredo
Oct 22, 2020·International Journal of Molecular Sciences·Denys PogozhykhConstança Figueiredo
Dec 16, 2020·Journal of Biomedical Materials Research. Part B, Applied Biomaterials·Sara Leal-MarinOleksandr Gryshkov
Mar 27, 2021·The American Journal of Sports Medicine·William H Fang, C Thomas Vangsness
Apr 4, 2021·International Journal of Molecular Sciences·Oleksandr GryshkovBirgit Glasmacher

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.